20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Protagonist Therapeutics Inc (PTGX) operates in the BIOTECHNOLOGY industry and is headquartered in Newark, United States with about 141 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, PTGX reported $46M in revenue and ($130M) in net income.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Interactive charts & full statements → Open the PTGX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $282M | $46M | $434M | $60M | $27M | $27M | $29M | $0M | $31M | $20M | $0M | $0M | $0M |
| Gross Profit | — | $45M | $434M | $60M | $27M | $27M | $29M | $0M | $31M | $20M | $0M | $0M | $0M |
| Gross Margin % | — | 97.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Income (EBIT) | $59M | ($158M) | $253M | ($94M) | ($131M) | ($126M) | ($65M) | ($81M) | ($42M) | ($38M) | ($33M) | ($15M) | ($9M) |
| Operating Margin % | 20.9% | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | -225.4% | -34857.6% | -136.7% | -188.9% | — | — | — |
| Net Income | $84M | ($130M) | $275M | ($79M) | ($123M) | ($126M) | ($66M) | ($77M) | ($39M) | ($37M) | ($37M) | ($15M) | ($11M) |
| Net Margin % | 29.8% | -282.8% | 63.3% | -131.6% | -464.3% | -458.9% | -231.1% | -33414.3% | -125.9% | -184.2% | — | — | — |
| EBITDA | — | ($128M) | $280M | ($76M) | ($128M) | ($123M) | ($64M) | ($77M) | ($42M) | ($37M) | ($32M) | ($15M) | ($9M) |
| Earnings Per Share (EPS) | $1.02 | $-2.05 | $4.23 | $-1.39 | $-2.52 | $-2.71 | $-1.92 | $-2.98 | $-1.74 | $-2.09 | $-5.72 | $-2.52 | $-1.88 |
| Shares Outstanding (M) | — | 64M | 65M | 57M | 49M | 46M | 34M | 26M | 22M | 18M | 7M | 6M | 6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $214M | $56M | $7M | $5M | $6M | $28M | $171M | $5M | $4M |
| Gross Profit | — | $56M | $7M | $5M | $6M | $28M | $171M | $5M | $4M |
| Gross Margin % | — | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | $159M | ($4M) | ($50M) | ($46M) | ($42M) | ($19M) | $127M | ($41M) | ($39M) |
| Operating Margin % | 74.3% | -6.5% | -677.1% | -985.2% | -758.0% | -68.2% | 74.3% | -886.7% | -931.0% |
| Net Income | $163M | $4M | ($44M) | ($39M) | ($35M) | ($12M) | $132M | ($33M) | ($31M) |
| Net Margin % | 76.2% | 6.7% | -596.8% | -834.9% | -627.0% | -41.1% | 77.2% | -710.4% | -734.7% |
| EBITDA | — | $3M | ($43M) | ($39M) | ($34M) | ($11M) | $134M | ($33M) | ($30M) |
| Earnings Per Share (EPS) | $2.29 | $0.05 | $-0.70 | $-0.62 | $-0.55 | $-0.19 | $1.98 | $-0.54 | $-0.50 |
| Shares Outstanding (M) | — | 70M | 64M | 64M | 64M | 63M | 66M | 62M | 61M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $131M | $58M | $184M | ($70M) | ($108M) | ($108M) | ($72M) | ($42M) | ($50M) | $4M | ($30M) | ($14M) | ($8M) |
| Capital Expenditures (CapEx) | $1M | $2M | $1M | $1M | $1M | $1M | $0M | $1M | $0M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $130M | $56M | $183M | ($71M) | ($109M) | ($109M) | ($73M) | ($42M) | ($50M) | $3M | ($30M) | ($15M) | ($8M) |
| FCF Margin % | 46.1% | 121.9% | 42.1% | -118.1% | -409.8% | -398.3% | -254.8% | -18395.7% | -163.1% | 16.0% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $219M | ($49M) | ($37M) | ($2M) | ($29M) | $125M | ($29M) | ($28M) | $269M |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $1M | $1M | $0M | $1M | $0M |
| Free Cash Flow (FCF) | $219M | ($49M) | ($38M) | ($2M) | ($30M) | $125M | ($29M) | ($29M) | $269M |
| FCF Margin % | 102.3% | -87.2% | -516.6% | -43.0% | -533.6% | 440.7% | -17.3% | -612.6% | 6445.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $886M | $670M | $745M | $358M | $248M | $348M | $324M | $155M | $139M | $164M | $94M | $15M | $10M |
| Cash & Cash Equivalents | $420M | $128M | $97M | $187M | $126M | $124M | $117M | $33M | $82M | $106M | $21M | $4M | $9M |
| Total Liabilities | $44M | $55M | $69M | $21M | $32M | $48M | $45M | $75M | $27M | $43M | $6M | $5M | $2M |
| Total Debt (Short + Long-Term) | — | $2M | $1M | $1M | $3M | $2M | $1M | $11M | $1M | $0M | $0M | $2M | $0M |
| Total Shareholders' Equity | $842M | $615M | $675M | $337M | $216M | $300M | $280M | $80M | ($140M) | ($102M) | ($65M) | $10M | $8M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PTGX viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms